The dysregulation of tight junctions leads to altered barrier function resulting in changes in levels of inflammatory cytokines such as IFN-α, IFN-γ, IL-6, and IL-1β as seen in inflammation-associated diseases such as multiple sclerosis and cancer (43–45). This evidence concerns the gene IFNG and cancer.